These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9137701)

  • 1. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal fat embolism following amphotericin B lipid complex injection.
    Tolentino LF; Tsai SF; Witt MD; French SW
    Exp Mol Pathol; 2004 Dec; 77(3):246-8. PubMed ID: 15507243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 6. Poor immediate tolerability of amphotericin B lipid emulsion in patients with haematological malignancies. Haematology-Microbiology Group.
    Laverdière M; Habel F; Weiss K; Delorme J; Dubois G; Gagnon N; Bélanger R
    J Antimicrob Chemother; 1997 Dec; 40(6):910-2. PubMed ID: 9462450
    [No Abstract]   [Full Text] [Related]  

  • 7. Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients.
    Annaloro C; Olivares C; Usardi P; Onida F; Della Volpe A; Tagliaferri E; Deliliers GL
    J Antimicrob Chemother; 2009 Mar; 63(3):625-6. PubMed ID: 19158110
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
    Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
    BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Herbrecht R; Letscher V
    J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B.
    Farmakiotis D; Tverdek FP; Kontoyiannis DP
    Clin Infect Dis; 2013 Mar; 56(5):701-3. PubMed ID: 23166189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Amphotericin B. Lipid complex versus liposomes. Which, why, when?].
    Pahissa A
    Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):1-3. PubMed ID: 9147499
    [No Abstract]   [Full Text] [Related]  

  • 12. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J; Markham L; Matulionyte R; Rives V; Lew D
    Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe and common side-effects of amphotericin B lipid complex (Abelcet).
    Ringdén O; Jønsson V; Hansen M; Tollemar J; Jacobsen N
    Bone Marrow Transplant; 1998 Oct; 22(7):733-4. PubMed ID: 9818706
    [No Abstract]   [Full Text] [Related]  

  • 14. Reader clarifies the use of amphotericin B.
    Madej T
    Oncol Nurs Forum; 1998 May; 25(4):653. PubMed ID: 9599340
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interactions with systemic antifungals in clinical practice.
    Depont F; Vargas F; Dutronc H; Giauque E; Ragnaud JM; Galpérine T; Abouelfath A; Valentino R; Dupon M; Hébert G; Moore N
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1227-33. PubMed ID: 17879355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible dilated cardiomyopathy associated with amphotericin B treatment.
    Moyssakis I; Vassilakopoulos TP; Sipsas NV; Perakis A; Petrou A; Kosmas N; Pangalis GA
    Int J Antimicrob Agents; 2005 May; 25(5):444-7. PubMed ID: 15848302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B in fat emulsion.
    Kintzel PE
    Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological risk factors for amphotericin B nephrotoxicity in children.
    Goldman RD; Ong M; Wolpin J; Doyle J; Parshuram C; Koren G
    J Clin Pharmacol; 2007 Aug; 47(8):1049-54. PubMed ID: 17525169
    [No Abstract]   [Full Text] [Related]  

  • 20. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
    Ozaras R; Yemisen M; Mete B; Mert A; Ozturk R; Tabak F
    Mycoses; 2007 May; 50(3):242. PubMed ID: 17472626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.